Trevena Soars on Positive Phase 2 Results

By Chris Lange Updated Apr 28, 8:45AM EDT · Published Aug 31, 4:34PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Trevena Inc. (NASDAQ: TRVN) watched its shares soar in Monday’s after-hours session on news of a positive Phase 2 trial. The company announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery.

For some background: Trevena is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors (GPCRs).

The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events.

Neil Singla, M.D., chief scientific officer of Lotus Clinical Research and lead investigator of the study, said:

The data from this trial showed that TRV130, when given on-demand, matched morphine efficacy for pain relief with a markedly improved safety and tolerability profile. The challenges of safely and adequately titrating morphine are well recognized, and these data suggest that, if approved, TRV130 may provide a better option than currently available opioid analgesics.

Maxine Gowen, Ph.D., CEO of Trevena, also commented on the results:

The positive data from this study continue the impressive accumulation of evidence suggesting meaningful differentiation of TRV130 from morphine. The goal of new analgesic drug discovery has long been the provision of more powerful pain relief with reduced opioid-related adverse effects. We believe the Trevena biased ligand platform has delivered this profile in TRV130 and we look forward to starting Phase 3 development in early 2016.

Shares of Trevena closed Monday down 0.7%, at $6.00 in its 52-week trading range of $3.80 to $8.16. In the after-hours trading session, shares were up 33.5% to $8.01. The stock has a consensus analyst price target of $13.94.

ALSO READ: 5 Big FDA Decisions Expected in September

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.